COZAAR

국가: 인도네시아

언어: 인도네시아어

출처: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

유효 성분:

LOSARTAN POTASSIUM

제공처:

ORGANON PHARMA INDONESIA TBK - Indonesia

INN (국제 이름):

LOSARTAN POTASSIUM

복용량:

50.0 MG

약제 형태:

TABLET SALUT SELAPUT

패키지 단위:

DUS, 2 BLISTER @ 15 TABLET SALUT SELAPUT

Manufactured by:

MERCK SHARP & DOHME LTD. - United Kingdom

승인 날짜:

2021-08-05

제품 특성 요약

_ _
Film Coated Tablets
COZAAR
®
(losartan potassium)
THERAPEUTIC CLASS
COZAAR
®
(losartan potassium), the first of a new class of antihypertensives,
is an angiotensin II receptor
(type AT1) antagonist.
INDICATIONS
COZAAR is indicated for the treatment of hypertension.
DOSAGE AND ADMINISTRATION
The
usual
starting
and
maintenance
dose
is
50
mg
once
daily
for
most
patients.
The
maximal
antihypertensive effect is attained 3-6 weeks after initiation of
therapy. Some patients may receive an
additional benefit by increasing the dose to 100 mg once daily.
For patients with intravascular volume-depletion (e.g., those treated
with high-dose diuretics), a starting
dose of 25 mg once daily should be considered (see PRECAUTIONS).
No initial dosage adjustment is necessary for elderly patients or for
patients with mild renal impairment
(i.e. creatinine clearance 20-50 mL/min). For patients with moderate
to severe renal impairment (i.e.
creatinine clearance <20 mL/min) or patients on dialysis, a lower
starting dose of 25 mg once daily is
recommended.
A
lower
dose
should
be
considered
for
patients
with
a
history
of
hepatic
impairment
(see
PRECAUTIONS).
COZAAR may be administered with other antihypertensive agents.
COZAAR may be administered with or without food.
CONTRAINDICATIONS
COZAAR is contraindicated in patients who are hypersensitive to any
component of this product.
COZAAR
should
not
be
administered
with
aliskiren
in
patients
with
diabetes
(see
DRUG
INTERACTIONS).
PRECAUTIONS
General: Although Cozaar is antihypertensive in all races; as with
other drugs that affect the renin-
angiotensin-aldosterone system, black hypertensive patients have a
smaller average response to losartan
monotherapy. If Cozaar is given together with thiazide-type diuretics,
the blood-pressure-lowering effects
are approximately additive. Losartan potassium administered in doses
of up to 150 mg once daily did not
cause clinically important changes in fasting triglyserides, total
cholesterol or HDL cholesterol, in patients
with hypertension. The sam